Tourmaline Bio, Inc. financial data

Symbol
TRML
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 13 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3155% % -20%
Debt-to-equity 2.9% % 0%
Return On Equity -30% % -32%
Return On Assets -30% % -60%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25,692,268 shares 0.2%
Common Stock, Shares, Outstanding 25,692,268 shares 0.17%
Entity Public Float $294,000,000 USD 227%
Common Stock, Value, Issued $3,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 25,755,000 shares 0.12%
Weighted Average Number of Shares Outstanding, Diluted 25,755,000 shares 0.12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $79,767,000 USD 105%
General and Administrative Expense $22,682,000 USD 2.5%
Operating Income (Loss) $102,449,000 USD -68%
Net Income (Loss) Attributable to Parent $88,474,000 USD -79%
Earnings Per Share, Basic -3 USD/shares -124%
Earnings Per Share, Diluted -3 USD/shares -124%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $31,423,000 USD -55%
Cash, Cash Equivalents, and Short-term Investments $231,700,000 USD 0.58%
Assets, Current $249,101,000 USD -16%
Property, Plant and Equipment, Net $47,000 USD -28%
Operating Lease, Right-of-Use Asset $127,000 USD -56%
Other Assets, Noncurrent $2,609,000 USD 117%
Assets $269,295,000 USD -22%
Accounts Payable, Current $3,170,000 USD 33%
Accrued Liabilities, Current $6,780,000 USD 81%
Liabilities, Current $10,095,000 USD 59%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $8,000 USD -79%
Liabilities $10,103,000 USD 55%
Accumulated Other Comprehensive Income (Loss), Net of Tax $121,000 USD
Retained Earnings (Accumulated Deficit) $181,323,000 USD -95%
Stockholders' Equity Attributable to Parent $259,192,000 USD -23%
Liabilities and Equity $269,295,000 USD -22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $21,679,000 USD -45%
Net Cash Provided by (Used in) Financing Activities $562,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $25,941,000 USD
Common Stock, Shares Authorized 140,000,000 shares 0%
Common Stock, Shares, Issued 25,692,268 shares 0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,824,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31,650,000 USD -55%
Deferred Tax Assets, Valuation Allowance $46,370,000 USD 36%
Deferred Tax Assets, Gross $49,469,000 USD 38%
Operating Lease, Liability $244,000 USD -41%
Depreciation $12,000 USD 20%
Payments to Acquire Property, Plant, and Equipment $9,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $87,901,000 USD -77%
Lessee, Operating Lease, Liability, to be Paid $265,000 USD -45%
Property, Plant and Equipment, Gross $132,000 USD 7.3%
Operating Lease, Liability, Current $145,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid, Year Two $38,000 USD -83%
Lessee, Operating Lease, Liability, to be Paid, Year One $227,000 USD 2.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.16 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,000 USD -70%
Lessee, Operating Lease, Liability, to be Paid, Year Three $0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards $11,233,000 USD 105%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $440,391,000 USD 2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $3,099,000 USD 68%
Share-based Payment Arrangement, Expense $8,155,000 USD 0.22%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%